Cargando…

Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?

Nearly twenty years ago a mutation in the VAPB gene, resulting in a proline to serine substitution (p.P56S), was identified as the cause of a rare, slowly progressing, familial form of the motor neuron degenerative disease Amyotrophic Lateral Sclerosis (ALS). Since then, progress in unravelling the...

Descripción completa

Detalles Bibliográficos
Autores principales: Borgese, Nica, Navone, Francesca, Nukina, Nobuyuki, Yamanaka, Tomoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243577/
https://www.ncbi.nlm.nih.gov/pubmed/37366377
http://dx.doi.org/10.1177/25152564211022515
_version_ 1785054452774862848
author Borgese, Nica
Navone, Francesca
Nukina, Nobuyuki
Yamanaka, Tomoyuki
author_facet Borgese, Nica
Navone, Francesca
Nukina, Nobuyuki
Yamanaka, Tomoyuki
author_sort Borgese, Nica
collection PubMed
description Nearly twenty years ago a mutation in the VAPB gene, resulting in a proline to serine substitution (p.P56S), was identified as the cause of a rare, slowly progressing, familial form of the motor neuron degenerative disease Amyotrophic Lateral Sclerosis (ALS). Since then, progress in unravelling the mechanistic basis of this mutation has proceeded in parallel with research on the VAP proteins and on their role in establishing membrane contact sites between the ER and other organelles. Analysis of the literature on cellular and animal models reviewed here supports the conclusion that P56S-VAPB, which is aggregation-prone, non-functional and unstable, is expressed at levels that are insufficient to support toxic gain-of-function or dominant negative effects within motor neurons. Instead, insufficient levels of the product of the single wild-type allele appear to be required for pathological effects, and may be the main driver of the disease. In light of the multiple interactions of the VAP proteins, we address the consequences of specific VAPB depletion and highlight various affected processes that could contribute to motor neuron degeneration. In the future, distinction of specific roles of each of the two VAP paralogues should help to further elucidate the basis of p.P56S familial ALS, as well as of other more common forms of the disease.
format Online
Article
Text
id pubmed-10243577
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102435772023-06-26 Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis? Borgese, Nica Navone, Francesca Nukina, Nobuyuki Yamanaka, Tomoyuki Contact (Thousand Oaks) Review Nearly twenty years ago a mutation in the VAPB gene, resulting in a proline to serine substitution (p.P56S), was identified as the cause of a rare, slowly progressing, familial form of the motor neuron degenerative disease Amyotrophic Lateral Sclerosis (ALS). Since then, progress in unravelling the mechanistic basis of this mutation has proceeded in parallel with research on the VAP proteins and on their role in establishing membrane contact sites between the ER and other organelles. Analysis of the literature on cellular and animal models reviewed here supports the conclusion that P56S-VAPB, which is aggregation-prone, non-functional and unstable, is expressed at levels that are insufficient to support toxic gain-of-function or dominant negative effects within motor neurons. Instead, insufficient levels of the product of the single wild-type allele appear to be required for pathological effects, and may be the main driver of the disease. In light of the multiple interactions of the VAP proteins, we address the consequences of specific VAPB depletion and highlight various affected processes that could contribute to motor neuron degeneration. In the future, distinction of specific roles of each of the two VAP paralogues should help to further elucidate the basis of p.P56S familial ALS, as well as of other more common forms of the disease. SAGE Publications 2021-06-15 /pmc/articles/PMC10243577/ /pubmed/37366377 http://dx.doi.org/10.1177/25152564211022515 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Borgese, Nica
Navone, Francesca
Nukina, Nobuyuki
Yamanaka, Tomoyuki
Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?
title Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?
title_full Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?
title_fullStr Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?
title_full_unstemmed Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?
title_short Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?
title_sort mutant vapb: culprit or innocent bystander of amyotrophic lateral sclerosis?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243577/
https://www.ncbi.nlm.nih.gov/pubmed/37366377
http://dx.doi.org/10.1177/25152564211022515
work_keys_str_mv AT borgesenica mutantvapbculpritorinnocentbystanderofamyotrophiclateralsclerosis
AT navonefrancesca mutantvapbculpritorinnocentbystanderofamyotrophiclateralsclerosis
AT nukinanobuyuki mutantvapbculpritorinnocentbystanderofamyotrophiclateralsclerosis
AT yamanakatomoyuki mutantvapbculpritorinnocentbystanderofamyotrophiclateralsclerosis